Journal article · 2026

Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer

Thomas B. Powles, Enrique Grande, Giuseppe Simone, Alfonso Gómez de Liaño, Marco Maruzzo, Pedro Henrique Isaacsson Velho, Eiji Kikuchi, Toan Quang Vu, LAZAR S. POPOVIC, Timuçin Çil, Gwénaëlle Gravis, Robert Radkowski and 13 more

New England Journal of Medicine · Published 24 October 2026 · DOI 10.1056/nejmoa2608323

View at the publisherCite this paper

In brief

“Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer” is a 2026 journal article by Thomas B. Powles and 24 co-authors, published in New England Journal of Medicine. OpenAlex counts 2 citations as of 16 November 2026, which puts it in the top 5% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
2
Most cited in
2026 (2)
Field-weighted impact
8.63
References
23
Authors
25

Abstract

BACKGROUND: The standard of care for patients with muscle-invasive bladder cancer continues to evolve. Whether perioperative durvalumab, with or without tremelimumab, plus neoadjuvant enfortumab vedotin is effective in such patients is unknown. METHODS: In this phase 3 open-label trial, we randomly assigned, in a 1:1:1 ratio, patients with muscle-invasive bladder cancer who were ineligible for… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Powles, T. B., Grande, E., Simone, G., de Liaño, A. G., Maruzzo, M., Velho, P. H. I., Kikuchi, E., Vu, T. Q., POPOVIC, L. S., Çil, T., Gravis, G., Radkowski, R., Hernández, L. R. N., Cutuli, H. J., Bamias, A., Bauernhofer, T., Pavic, M., Choi, Y. J., Chang, C.-H., . . . Drakaki, A. (2026). Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2608323

MLA 9

Powles, Thomas B., et al. “Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer.” New England Journal of Medicine, 2026. https://doi.org/10.1056/nejmoa2608323.

Chicago

Powles, Thomas B., Enrique Grande, Giuseppe Simone, Alfonso Gómez de Liaño, Marco Maruzzo, Pedro Henrique Isaacsson Velho, Eiji Kikuchi, et al. 2026. “Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer.” New England Journal of Medicine. https://doi.org/10.1056/nejmoa2608323.

Harvard

Powles, T. B. et al. (2026) ‘Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer’, New England Journal of Medicine. doi:10.1056/nejmoa2608323.

IEEE

T. B. Powles et al., “Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer,” New England Journal of Medicine, 2026, doi: 10.1056/nejmoa2608323.

BibTeX

@article{powles2026durvalumab,
  title     = {{Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer}},
  author    = {Powles, Thomas B. and Grande, Enrique and Simone, Giuseppe and de Liaño, Alfonso Gómez and Maruzzo, Marco and Velho, Pedro Henrique Isaacsson and Kikuchi, Eiji and Vu, Toan Quang and POPOVIC, LAZAR S. and Çil, Timuçin and Gravis, Gwénaëlle and Radkowski, Robert and Hernández, Luis Raúl Novelo and Cutuli, Hernán Javier and Bamias, Aristotelis and Bauernhofer, Thomas and Pavic, Michel and Choi, Yoon Ji and Chang, Chao-Hsiang and Kitamura, Hiroshi and Rosenberg, Jonathan E. and Rowbottom, Jacqui and Ho, Svetlana and Gupta, Ashok and Drakaki, Alexandra},
  journal   = {New England Journal of Medicine},
  year      = {2026},
  doi       = {10.1056/nejmoa2608323},
  url       = {https://doi.org/10.1056/nejmoa2608323}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Surgery › Bladder and Urothelial Cancer Treatments

  • muscle-invasive bladder cancer
  • durvalumab
  • tremelimumab
  • enfortumab vedotin
  • neoadjuvant immunotherapy
  • adjuvant immunotherapy
  • radical cystectomy
  • event-free survival

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Powles, T. B., Grande, E., Simone, G., de Liaño, A. G., Maruzzo, M., Velho, P. H. I., Kikuchi, E., Vu, T. Q., POPOVIC, L. S., Çil, T., Gravis, G., Radkowski, R., Hernández, L. R. N., Cutuli, H. J., Bamias, A., Bauernhofer, T., Pavic, M., Choi, Y. J., Chang, C.-H., . . . Drakaki, A. (2026). Durvalumab, Tremelimumab, and Enfortumab Vedotin in Muscle-Invasive Bladder Cancer. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2608323

How many times has this paper been cited?

2 times, according to OpenAlex on 16 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Thomas B. Powles, Enrique Grande, Giuseppe Simone, Alfonso Gómez de Liaño, Marco Maruzzo, Pedro Henrique Isaacsson Velho, Eiji Kikuchi, Toan Quang Vu, LAZAR S. POPOVIC, Timuçin Çil, Gwénaëlle Gravis, Robert Radkowski and 13 more.

What is the DOI of this paper?

10.1056/nejmoa2608323, permanently at https://doi.org/10.1056/nejmoa2608323. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 16 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.